Serum proteome analysis of systemic JIA and related pulmonary alveolar proteinosis identifies distinct inflammatory programs and biomarkers

Competing Interest Statement

VS reports personal fees from Novartis, grants from Novartis, outside the submitted work. SC reports grants from Systemic JIA Foundation, grants from NICHD, grants from RK Mellon Institute, during the conduct of the study; grants from AB2Bio, Ltd., other from Simcha Therapeutics, grants from IMMvention Therapeutix, outside the submitted work. RG-M reports grants from Systemic JIA Foundation during the conduct of the study; grants from Lilly, grants from SOBI outside the submitted work. EM reports grants from Lucille Packard Foundation for Children Health, grants from CARRA-Arthritis Foundation, during the conduct of the study; grants from Novartis, grants from GSK, outside the submitted work. PK reports personal fees and other from Inflammatix, Inc., personal fees from Cepheid, outside the submitted work. GS reports personal fees from Novartis, personal fees from SOBI, outside the submitted work. GD reports personal fees from Novartis Pharmaceuticals, outside the submitted work. AG reports grants and personal fees from Sobi, grants and personal fees from Novartis, grants and personal fees from AB2Bio, during the conduct of the study.

Funding Statement

The SOMAscan assay was supported by a grant to the Intramural Research Program of the NIAID from the Systemic JIA Foundation. AAdJ and RGM were supported by the NIAID intramural research program. GC is an Eli Lilly Fellow of the Life Science Research Foundation. SJ is supported by Dean Postdoctoral Fellowship, School of Medicine, Stanford. CM and EDM were supported by NIAMS R01 AR066551, AR061297 and Arthritis Foundation Great West Region Arthritis Center of Excellence; VS and EDM were supported by the Lucille Packard Foundation for Children Health and a Childhood Arthritis and Rheumatology Research Alliance/Arthritis Foundation grant. CS and SWC were supported by the RK Mellon Institute for Pediatric Research, NIAID K22 AI123366, and NICHD R01 HD098428. PK is funded in part by the Bill and Melinda Gates Foundation (OPP1113682); NIAID 1U19AI109662, U19AI057229, and 5R01AI125197 grants; Department of Defense contracts W81XWH-18-1-0253 and W81XWH1910235; and the Ralph & Marian Falk Medical Research Trust.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics approval for collection of clinical data and patient serum through institutional review boards at the following institutions: Stanford University, University of Cincinnati, University of Pittsburgh and National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes